EUCTR2011-001429-25-NL进行中（未招募）不适用
Feasibility Study: FES-PET to determine ER-expression in epithelial ovarian cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Histological evidence or high clinical suspicion with proven malignant ascites and high probability of epithelial ovarian cancer
- •2.The presence of at least one measurable lesion (RECIST v1.1).
- •3.Histology or cytology can be obtained (may be ascites)
- •4.ECOG performance status 0-2.
- •5.Postmenopausal status (defined as either >45 years with amenorrhea >12 months, or prior bilateral ovariectomy)
- •6.No history of other ER-positive malignancies
- •7.Signed written informed consent
- •8.Able to comply with the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •1.Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, during the 5 weeks before entry into the study
- •2.Life-expectancy = 3 months
研究者
相似试验
进行中（未招募）
1 期
The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-a status in patients with metastatic breast cancer HER2 + and ERa neg treated with trastuzumab + pertuzumab + taxane.Metastatic breast cancer HER2 + and ERa neg.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2018-001552-36-FRINSTITUT CLAUDIUS REGAUD33
已完成
不适用
Examination of Clinical usefulness of FES-PET for hormone therapy against recurrence after adjuvant hormone therapy of estrogen receptor-positive breast cancerRecurrence of estrogen-positive breast cancerJPRN-UMIN000016488Institusion of Biomedical Resarch and Innovation10
撤回
2 期
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PETBreast CancerNCT03065712University of Texas Southwestern Medical Center
已完成
不适用
A pilot study of FES-PET for patients with breast cancerbreast cancerJPRN-UMIN000003124Institute of Biomedical Research and Innovation5
终止
不适用
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.HER2-positive Breast CancerNCT03619044Institut Claudius Regaud4